NOJECTION
LIVE

Serial Number

87749762

Owner

BIOHAVEN PHARMACEUTICAL IRELAND DAC

Attorney

Andrea Christensen

First Use Date

Jun 18, 2021

Filing Date

Jan 10, 2018

Add to watchlist:

No watchlists yet
View on USPTO

NOJECTION Trademark

Serial Number: 87749762 • Registration: 6479275

NOJECTION is a trademark filed by BIOHAVEN PHARMACEUTICAL IRELAND DAC on January 10, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

BIOHAVEN PHARMACEUTICAL IRELAND DAC (34 trademarks)

6TH FLOOR, SOUTH BANK HOUSE, BARROW
DUBLIN 4 D04TR29 , IE

Entity Type: 99

Biohaven Pharmaceutical Holding Company Limited (20 trademarks)

New Haven, CT 06510

Entity Type: 99

Trademark Details

Filing Date

January 10, 2018

Registration Date

September 7, 2021

First Use Anywhere

June 18, 2021

First Use in Commerce

June 18, 2021

Published for Opposition

May 1, 2018

Goods & Services

Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Sep 7, 2026 REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Sep 7, 2026 REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Sep 7, 2026 REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Sep 7, 2026 REM1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 27, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 27, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 27, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 27, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 27, 2022 COAR
REGISTERED-PRINCIPAL REGISTER
Sep 7, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Aug 4, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 3, 2021 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jun 27, 2021 SUPC
USE AMENDMENT FILED
Jun 24, 2021 IUAF
TEAS STATEMENT OF USE RECEIVED
Jun 24, 2021 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 24, 2020 EXRA
SOU EXTENSION 5 GRANTED
Dec 23, 2020 EX5G
SOU EXTENSION 5 FILED
Dec 21, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Dec 21, 2020 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 19, 2020 ASGN
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 1, 2020 EXRA
SOU EXTENSION 4 GRANTED
Jun 30, 2020 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 30, 2020 AITU
SOU EXTENSION 4 FILED
Jun 17, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 17, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 21, 2019 EXRA
SOU EXTENSION 3 GRANTED
Dec 19, 2019 EX3G
SOU EXTENSION 3 FILED
Dec 19, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 19, 2019 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 23, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 23, 2019 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 25, 2019 EXRA
SOU EXTENSION 2 GRANTED
Jun 21, 2019 EX2G
SOU EXTENSION 2 FILED
Jun 21, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 21, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 12, 2018 EXRA
SOU EXTENSION 1 GRANTED
Sep 10, 2018 EX1G
SOU EXTENSION 1 FILED
Sep 10, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 10, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 26, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 1, 2018 NPUB
PUBLISHED FOR OPPOSITION
May 1, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 11, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 27, 2018 CNSA
ASSIGNED TO EXAMINER
Mar 27, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 24, 2018 NWOS
NEW APPLICATION ENTERED
Jan 13, 2018 NWAP